# HistoSonics: robotics company

Canonical ID: `fffa2127-5d46-4965-b510-cf96161154f0`

## Key facts

- **Funding:** [$102M Series D + $2B+ acquisition](/investors.md) ([see investors](/investors.md))
- **CEO:** Mike Blue
- **Form factor:** Surgical (histotripsy / focused ultrasound)
- **FDA status:** De Novo authorized 2023 (liver); kidney pending
- **CE Mark:** July 2026
- **Founded:** 2009
- **Stage:** Commercial (FDA-cleared)
- **Product:** [Edison Histotripsy System](/models/histosonics-edison.md) (FDA De Novo cleared Oct 2023)
- **Total funding:** [$102M+ Series D (Alpha Wave Ventures led)](/investors.md) ([see investors](/investors.md))
- **Valuation:** [$3.75B (2026)](/valuations.md) ([see valuations ranking](/valuations.md))
- **FDA pathway:** De Novo clearance for liver tumor destruction
- **Investors:** [Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation](/investors.md) ([see investors](/investors.md))

- **Slug:** histosonics
- **Founded:** 2009
- **HQ:** Plymouth, MN, USA
- **Valuation of record:** $3.8B (Company-claimed, as of Jun 2026; Priced round: [Series D post-money](https://histosonics.com/histosonics-secures-102m-series-d-financing/)) · [see valuations ranking](/valuations.md)
- **Category:** [Surgical robots](/surgical)

## Models

- [Edison Histotripsy System](/models/histosonics-edison.md) (surgical) (id: `1ede4325-d956-495d-b01b-3e5ffad096a9`)

## Current leadership (1)

- [Steve Augustine](/people/steve-augustine.md) CEO (_reported, not verified_)

## Supplies to

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this company's outbound edges._

_Outbound supply edges. Each appears when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Common questions

### What is HistoSonics?

Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.

### What does HistoSonics make?

HistoSonics has 1 robot model on the DEPLOY registry: Edison Histotripsy System (HistoSonics builds physical robots).

### Where is HistoSonics headquartered?

HistoSonics is headquartered in Plymouth, MN, USA.

### Where does HistoSonics operate robots?

HistoSonics is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.

### When was HistoSonics founded?

HistoSonics was founded in 2009.


## Sources (4)

1. https://histosonics.com/
2. https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/
3. https://histosonics.com/histosonics-secures-102m-series-d-financing/
4. https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/

_API: GET /v1/companies/fffa2127-5d46-4965-b510-cf96161154f0 · canonical URL: /companies/histosonics_